Age (> 50 or < 50 years), sex (male or female), neutropenia, severe neutropenia, anemia, the presence of PRCA, T-cell subtype (αβ or γδ), the predominancy of CD56, CD4 or CD8, and the presence of STAT 3/5 mutation did not differ among the treatment responses (Supplement 1). This evidence concerns the gene NCAM1 and pure red-cell aplasia.